www.youtube.com/watch?v=hJyV8dZA-Qw

See the original post:
Pony Genetics – Video

Originally posted here:
Signal Genetics Agrees to Purchase ChipDX to Gain Cancer Diagnostics

Researcher: Genetics impacts everyone

BY AUDREY DWYER | FEBRUARY 02, 2012 7:20 AM

Popular genetics affects everyone.

That's the message of Spencer Wells, the director of the National Geographic Genographic Project, who described to University of Iowa students on Wednesday how genetic research uncovers hidden ties in society.

“It's a story about all of us,” he said.

He is leading a global expedition to collect DNA samples from various indigenous human populations. These samples are being used to record history of human migrations that began in Africa and spread throughout the world.

“The average person doesn't think of genetics as being terribly relevant to her or him,” he told The Daily Iowan. “I think what this study does is raise awareness about genetics to the average person who is not a genetics scientist.”

Wells — who became curious in genetics when he was 10 years old in a biology lab with his mother — said the lecture was an opportunity to bring the excitement of genetics to students in all different areas of study.

He spoke at the Englert Theatre, 221 E. Washington St., about his research experience in roughly 80 countries.

In Wells' research, scientists are able to study how the Y chromosome, found in most male mammals, traces ancestral lineage.

Dan Eberl, the director of the UI's interdisciplinary Ph.D. program in genetics, said the program helps train students to be independent thinkers.

“This enables us to expose our students to a wide variety of studies; these ideas are really important,” he said.

Though the number of students in the program has remained steady over the past few years, averaging roughly 45 students, Eberl said the program has expanded significantly through the numerous interdisciplinary programs.

John Manak, a UI assistant professor of genomics and genetics, said several projects underway in the genetics program examine ways to improve medicine.

Manak stressed the importance of Wells' study in his explanation of human ancestry. The study helps answer the question of human identity and origin simply by looking at DNA.

The UI initially had a basic genetics program, but as developments in the field grew over time, the university expanded opportunities for students. Genetics has become an interdisciplinary field at the university, with officials hiring additional faculty through cluster hiring.

Lily Paemka, a graduate student in genetics, said while she feels genetics is obviously important, giving the community an opportunity to listen to a well-known researcher such as Wells may inspire future generations.

“Hopefully, we will also catch the attention of promising future scientists and maybe even convert some,” she said.

In today's issue:

View the discussion thread.comments powered by

View original post here:
Researcher: Genetics impacts everyone

Link:
Viral Genetics Inc. Issues 2011 Year in Review and 2012 Outlook

NEW YORK–(BUSINESS WIRE)– Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced an agreement with New York based ChipDX LLC (“ChipDX”), under which Signal will acquire all of the assets of ChipDX, including patents for prognostic tests in lung, breast, and colon cancers. As part of the transaction, Signal will acquire BreastGeneDX®, ColonGeneDX®, and LungGeneDX®, all diagnostic and prognostic tests in development by ChipDX. Signal believes that these genetic tests represent novel products or improvements over other products currently on the market in these cancer types. Signal will also acquire ChipDX’s web-based interface, which will be used to enhance Signal’s physician web portal and allow for remote interpretation of test algorithms. Ryan VanLaar, Ph.D., CEO and Founder of ChipDX, will join Signal as the Head of BioInformatics. Financial details of the transaction were not disclosed.

ChipDX has been recognized by leading molecular diagnostics companies and academic centers for its work in various types of cancer, including most recently for its work on the BreastGeneDX® prognostic test. The acquired tests will leverage the technology platform currently in use by Signal Genetics and its subsidiaries and will provide economies of scale to the Company’s currently commercialized Multiple Myeloma prognostic test, MyPRS Plus™. Additionally, Signal Genetics will leverage its recently established sales team as well as its commercial partners to launch the acquired products.

“The acquisition of the intellectual property and patents of ChipDX dramatically expands and enhances our oncology pipeline,” said Joe Hernandez, President and CEO of Signal. “The addition of ChipDX’s bioinformatics capabilities drastically reduces our time to market with novel molecular tests designed to facilitate better patient outcomes at a lower cost profile. We are also thrilled to have Ryan VanLaar join our team and we welcome him to Signal. This transaction is consistent with our strategy to develop and acquire innovative tools that both complement and enhance our product portfolio.”

Ryan van Laar, CEO and Founder of ChipDX LLC, said, “Joining forces with Signal Genetics provides us with a vehicle to ultimately commercialize our strong portfolio of predictive molecular diagnostic tests. I look forward to leveraging the experience gained in the development of ChipDX to help Signal Genetics achieve its goals, and ultimately improve patient outcomes.”

About ChipDX LLC

ChipDX LLC is a privately held molecular diagnostics and personalized medicine company based in New York City. It was founded and is currently lead by Ryan VanLaar, Ph.D.

About Signal Genetics

Signal Genetics, the parent company of Myeloma Health LLC, CC Health, Respira Health, and ChipDX, is a privately held predictive genetic testing company focused on helping cancer patients. The goal of Signal Genetics is to provide cancer patients and their physicians with novel and innovative insights into their disease, including predicting outcomes, accurately staging disease, providing odds of relapse, and identifying the optimal treatment regimen based on their specific genetic expression profile. Additional information is available at www.signalgenetics.com

More:
Signal Genetics Announces Acquisition of ChipDX LLC and Expansion of Molecular Diagnostics Assets in Oncology

More here:
Myriad Genetics Outruns Estimates Again

Read the original here:
Myriad Genetics Reports Second Quarter Fiscal Year 2012 Results

Follow this link:
Genetics Pioneer Was UConn Professor, Mentor

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NASDAQ:SGEN – News) announced today that it will report its fourth quarter and year 2011 financial results on Monday, February 13, 2012, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Monday, February 13, 2012

1:30 p.m. Pacific Time (PT) / 4:30 p.m. Eastern Time (ET)

REPLAY access

Telephone replay will be available beginning at approximately 3:30 p.m. PT on Monday, February 13, 2012, through 5:00 p.m. PT on Wednesday, February 15, 2012, by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4509854 Webcast replay will be available on the Seattle Genetics website at http://www.seattlegenetics.com in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The FDA granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Read more from the original source:
Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2011 Financial Results on …

See the original post:
Range-bound play on Myriad Genetics

CHARLEROI, Belgium–(BUSINESS WIRE)– The Belgian Biotech
Company Delphi Genetics SA is proud to announce the launch of
a newly-funded project. Together with academic and Biotech
key-players, the company will participate in the development
of DNA vaccines using the Staby® technology (antibiotic-free)
during the next 3 years. The objective of the project funded
by the Walloon region (BioWin project, 2.3 M €) is to develop
and produce antibiotic-free DNA vaccines targeting some
veterinary diseases.

The project also involves Eurogentec SA, another Belgian
Biotech company (part of Kaneka) in charge of large scale DNA
production and purification, and two universities: the
Catholic University of Louvain in charge of the
pharmaceutical and toxicity aspects of the project and the
University of Liège in charge of the vaccinology and
veterinary issues. “All partners complement one another
perfectly” said Cédric Szpirer, CEO and Head of R&D of
Delphi Genetics SA and explained:

“Today vaccination is an uncontested way of fighting disease.
DNA vaccination seems to be a particularly promising method
at this time, especially in the case of veterinary diseases.
However, antibiotic-resistance genes are conventionally used
during the construction of DNA vaccines but the resistance is
increasingly less tolerated by regulatory agencies (FDA, USDA
and EMA). In the context of this project, we propose to
replace the antibiotic-resistance gene by the Staby®
technology developed by Delphi Genetics and already used for
production of recombinant proteins (higher yields and no
antibiotics). In order to show the efficiency of our
technology, we will develop new veterinary vaccines, we will
validate that the method is usable for high scale DNA
production and we will show its innocuousness.”

About Delphi Genetics

Founded at the end of 2001, Delphi Genetics SA develops
technologies for genetic engineering and protein expression
by using unique expertise in the domain of plasmid
stabilisation systems.

Since 2004, Delphi Genetics has been marketing innovative
kits for researchers. Some of these kits contain technologies
that have since been licensed for industrial applications; in
2009 Delphi Genetics announced a non-exclusive licence
agreement with Sanofi-Pasteur, the human vaccine division of
Sanofi and a non-exclusive agreement with GSK in 2010. These
agreements allow Sanofi-Pasteur and GSK to apply the
StabyExpress® technology in the production of recombinant
proteins, thus enabling them to produce a high yield without
using antibiotics.

For more information, visit our website:
www.delphigenetics.com

The rest is here:
Delphi Genetics: The New DNAVAC Research Project Targets the Removal of Antibiotics in Veterinary DNA-Vaccine …

Go here to see the original:
Genetics study reveals how bacteria behind serious childhood disease evolve to evade vaccines

Read more:
Genetics study reveals how pneumococcus bacteria evolve to evade vaccines